GSA Capital Partners’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

GSA Capital Partners’s Portfolio BXRX Stock Details BXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-496	Closed	-$152K	–	1986
2021 Q4	$152K	Buy	+496	New	+$311K	0.02%	1270
2021 Q2	–	Sell	-13	Closed	-$24K	–	1718
2021 Q1	$24K	Sell	13 -145	-92%	-$290K	﹤0.01%	1047
2020 Q4	$223K	Buy	+158	New	+$323K	0.04%	923

Other funds holding BXRX

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

GSA Capital Partners's BXRX Position: Q1 2022 in Review

GSA Capital Partners sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q1 2022, closing a stake of 496 shares — an estimated $152K sold.

GSA Capital Partners first reported a position in BXRX in Q4 2020 and held it in 3 quarters. The position peaked at $223K in Q4 2020. 19 funds tracked by Wall St. Rank hold BXRX as of Q1 2022.

GSA Capital Partners reported no remaining Baudax Bio, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
GSA Capital Partners sold 496 Baudax Bio, Inc. Common Stock shares in Q1 2022, an estimated $152K.
GSA Capital Partners first reported a position in Baudax Bio, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
GSA Capital Partners's Baudax Bio, Inc. Common Stock position peaked at $223K in Q4 2020.
19 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q1 2022.

Based on GSA Capital Partners's 13F filing for Q1 2022, filed 11 May 2022.